ERA-923 in Treating Postmenopausal Women With Metastatic Breast Cancer

Status unconfirmed · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ERA-923 may fight breast cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of ERA-923 in treating postmenopausal women who have metastatic breast cancer that no longer responds to tamoxifen.

Key facts

Study ID

NCT00006369

Run by

H. Lee Moffitt Cancer Center and Research Institute

Starts

2000-06-01

Last updated by the study team

2013-11-06

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

Where it is running

• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.